Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | IDUA | P35475 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18911637 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL12346259 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL13618641 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL1669031 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL24212766 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL23720424 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL13792996 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL15061094 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL21097517 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA | |
| SCHEMBL17828572 | 1.00 | SUCNR1 (0.39) | SUCNR1THRBLMNATDP1IDUA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023170239-A1 | METHODS AND TOOLS FOR CONJUGATION TO ANTIBODIES | MERCK PATENT GMBH (DE) | 2023-09-14 | — | — | WO | disclosed |
| US-11707476-B2 | Catecholamine prodrugs for use in the treatment of parkinson's disease | H. LUNDBECK A/S (DK) | 2023-07-25 | — | — | US | disclosed |
| US-11707476-B2 | Catecholamine prodrugs for use in the treatment of parkinson's disease | H. LUNDBECK A/S (DK) | 2023-07-25 | — | — | US | disclosed |
| US-20220257623-A1 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | H. LUNDBECK A/S (DK) | 2022-08-18 | — | — | US | disclosed |
| US-20220213072-A1 | METABOLITES OF GLP1R AGONISTS | PFIZER INC. (US) | 2022-07-07 | — | — | US | disclosed |
| WO-2022048883-A1 | ANTI-CEACAM5 ANTIBODIES AND CONJUGATES AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-03-10 | — | — | WO | disclosed |
| US-11167040-B2 | Conjugates comprising peptide groups and methods related thereto | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-11-09 | — | — | US | disclosed |
| US-11110110-B2 | Catecholamine prodrugs for use in the treatment of Parkinson's disease | H. LUNDBECK A/S (DK) | 2021-09-07 | — | — | US | disclosed |
| US-20210032250-A1 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-02-04 | — | — | US | disclosed |
| WO-2018138591-A1 | CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2018-08-02 | — | — | WO | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2017122495-A1 | CERAMIDE CONTENT INCREASING AGENTS | 国立大学法人富山大学 | 2017-07-20 | — | — | WO | disclosed |
| WO-2017089890-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089895-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089894-A1 | CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| US-20170065615-A1 | Steroid Analogues for Neuroprotection | UNIV EMORY (US) | 2017-03-09 | — | — | US | disclosed |
| WO-2015110935-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| EP-2107055-A1 | Diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2009-10-07 | — | — | EP | disclosed |
| WO-2003027060-A1 | DIPHENYLBUTANE AMIDE DERIVATIVES | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | SUCNR1 213/4885THRB 285/4885LMNA 3944/4885 |
| US-11167040-B2 | Conjugates comprising peptide groups and methods related thereto | DAO, LPO, TYRO3 | SUCNR1 1965/4885THRB 1680/4885LMNA 4642/4885 |
| US-20220213072-A1 | METABOLITES OF GLP1R AGONISTS | GLP1R, GCGR, GIPR | SUCNR1 401/4885THRB 938/4885LMNA 1622/4885 |
| US-20210032250-A1 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS | JAK1, UGT1A1, JAK2 | SUCNR1 624/4885THRB 2777/4885LMNA 4707/4885 |
| US-20220257623-A1 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | COMT, SLC6A2, SLC6A3 | SUCNR1 193/4885THRB 1187/4885LMNA 3080/4885 |
| US-11110110-B2 | Catecholamine prodrugs for use in the treatment of Parkinson's disease | COMT, SLC6A2, SLC6A3 | SUCNR1 224/4885THRB 1283/4885LMNA 2866/4885 |
| US-20170065615-A1 | Steroid Analogues for Neuroprotection | CYP11A1, NR3C2, HSD17B7 | SUCNR1 1746/4885THRB 1429/4885LMNA 831/4885 |
| US-11707476-B2 | Catecholamine prodrugs for use in the treatment of parkinson's disease | COMT, SLC6A2, MAOB | SUCNR1 1349/4885THRB 1622/4885LMNA 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.